Budesonide/Glycopyrronium/Formoterol: A Review in COPD

Physiology May be the Key: Cardiovascular Risk Stratification in OSA

(2021) Bhajan Singh   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

(2021) Arnaud Bourdin et al.   ADVANCES IN THERAPY

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review

(2020) Shiyuan Zhang et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS

(2020) Chen Wang et al.   ADVANCES IN THERAPY

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

(2020) Gary T. Ferguson et al.   ADVANCES IN THERAPY

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

(2020) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

FUNCTIONAL RESPIRATORY IMAGING ASSESSMENT OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE AND GLYCOPYRROLATE/FORMOTEROL FUMARATE METERED DOSE INHALERS IN PATIENTS WITH COPD

(2020) M. van den Berge et al.   CHEST

A SCINTIGRAPHY STUDY OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE IN PATIENTS WITH COPD

(2020) Omar Usmani et al.   CHEST

Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies

(2020) Luigino Calzetta et al.   Expert Review of Respiratory Medicine

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for COPD: A Randomized, Double-Blind, Multi-Center Parallel-Group Study

(2020) Fernando J. Martinez et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD

(2019) Luigino Calzetta et al.   CHEST

Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study

(2019) Qian Chen et al.   CLINICAL THERAPEUTICS

Glycopyrronium/Formoterol: A Review in COPD

(2019) Zaina T. Al-Salama et al.   DRUGS

Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD

(2019) Leonard J. Dunn et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD

(2019) Masakazu Ichinose et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study

(2019) Masakazu Ichinose et al.   International Journal of Chronic Obstructive Pulmonary Disease

The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults

(2018) Patrick Darken et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

(2018) Gary T Ferguson et al.   Lancet Respiratory Medicine

Budesonide/Formoterol Turbuhaler®

(2012) Lesley J. Scott   DRUGS